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ABSTRACT 
The extracellular matrix (ECM) is an essential requirement for maintaining permanent 
shape and rigidity in multicellular organisms. The ECM serves two main functions: scaffolding 
and signaling. Insoluble collagen and soluble proteoglycans, glycosaminoglycans (GAGs), and 
glycoproteins allow for water retention and flexibility. The signaling role of the ECM is essential 
for a multitude of events including vascular development and angiogenesis. Via interactions with 
vascular endothelial cells, proteins of the ECM can induce or repress angiogenesis.  
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PREFACE 
The aim of this thesis is to demonstrate the importance of ECM proteins as regulators of 
angiogenesis  in  general  and  to  highlight  my  research  on  the  proteins  Lumican,  Clusterin, 
Nephronectin, SerpinE2, and Gremlin-1 as they relate to angiogenesis.   v 
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CHAPTER 1 
 
EXTRACELLULAR MATRIX PROTEINS: IMPLICATIONS FOR ANGIOGENESIS 
 
What  comprises  a  complex  multicellular  organism?  Most  would  consider  the  classic 
understanding  of  systems  composed  of  organs,  organs  composed  of  tissues,  and  tissues 
composed  of  cells.  This  view  however,  completely  overlooks  an  essential  element  in  the 
structuring  and  functioning  of  such  an  organism:  the  extracellular  matrix.  The  extracellular 
matrix (ECM) is an evolutionarily conserved substrate consisting of a variety of structural and 
signaling molecules secreted from differentiated mesenchymal cells including chondrocytes and 
fibroblasts [1]. Every cellular function from development to differentiation to reproduction to 
death involves the ECM in one way or another. 
 
Extracellular matrix: an evolutionary perspective 
Basement membranes are some of the oldest and best conserved extracellular matrices 
[2]. Because such matrices are essential to complex and permanent organismal structure, some 
have suggested the formation of extracellular matrix provides evidence of a monophyletic origin 
of the animal kingdom [3]. Basement membranes consist of laminin, collagen IV, and additional 
proteins  to  provide  structural  support  and  sites  for  cellular  anchoring.  Laminins  have  been 
identified  in  organisms  as  simple  as  C.  elegans  [2].  The  collagen  IV  observed  in  basement 2 
membranes is arguably one of the oldest matrix proteins as it appears in simple organisms such 
as C. elegans and members of the phylum Porifera [2-3].  
 
Extracellular matrix: form and function 
The ECM consists of an aggregation of soluble and insoluble factors. In vertebrates (and 
some invertebrates), collagen provides a rigid, insoluble boundary for structures. Other elements 
in the matrix swell in water to resist compressive force and maintain structural shape. One such 
water soluble molecule, hyaluronic acid, is an abundant nonsulfated glycosaminoglycan (GAG) 
of the ECM. GAGs are charged amino sugar chains and are often found attached to a protein 
backbone. The resulting large branched molecules are known as proteoglycans. Glycoproteins 
are secreted proteins glycosylated by N-linked oligosaccharides, and represent important soluble 
members of the ECM [3]. 
The  ECM  serves  two  major  functions:  providing  structure  and  regulating  cellular 
activities via outside-in signaling. Insoluble and soluble elements both play an important role in 
defining structure and providing sites for cellular attachment. But it would be an error to consider 
the ECM a lifeless molecular skeleton. On the contrary, many of the molecules of the ECM act 
as matrikines to relay signals to the surrounding cells. Matrikines are ECM proteins which act as 
ligands  for  cell  surface  receptors  [4].  The  ECM  affects  a  plethora  of  processes  within  an 
organism. One condition in which the ECM is intimately involved is the process of angiogenesis 
[5]. 
 3 
Angiogenesis 
Angiogenesis is the development of new blood vessels from the existing host vasculature 
[6]. The process of angiogenesis can be thought of as several unique events. The blood vessel 
must  be  stimulated  to  initiate  the  breaching  of  the  vessel  wall.  Surrounding  tissue  must  be 
degraded, often by matrix metalloproteinases (MMPs), or avoided while the endothelial cells 
migrate and invade to the region requiring vascularization [7]. Supporting cells, such as smooth 
muscle cells and pericytes are recruited to reform the vascular tubule. Finally, the newly formed 
vessel  must  slow  this  process  down  and  return  to  angiostasis.  Each  of  these  distinct  stages 
requires interactions with the ECM. 
Angiogenesis arises under a number of conditions in the healthy adult human. Examples 
include during exercise, prior to menstruation, and during wound healing [8]. There are other 
instances where angiogenesis is the result of an underlying pathology. There are over 70 human 
diseases associated with a disproportionate amount of angiogenesis [9]. One example of this is 
the  increase  in  angiogenesis  associated  with  tumor  growth.  Tumor  cells,  like  healthy  cells, 
require nutrients and oxygen to survive. Oxygen is only able to diffuse approximately 110 µm 
beyond the vasculature and therefore requires blood vessels for efficient cellular transport [10]. 
To maintain their rapid growth and survival, as well as to establish a pathway for metastasis, 
tumors encourage the growth of new vasculature. This requires the manipulation of the tumor 
microenvironment by the tumor. The hypoxic condition of the tumor stroma, as well as proteins 
secreted by the tumor cells into the microenvironment, provide cues to the invading endothelial 
cells to encourage migration [6]. Tumors exploit existing ECM proteins and signaling pathways 
to encourage angiogenesis. Identifying and characterizing the constituents of the extracellular 
matrix and the signaling pathways they manipulate provides new avenues for the treatment of the 4 
many diseases associated with pathological angiogenesis. Many of the proteins I will discuss are 
involved in multiple pathways and these pathways may interact with one another in a positive or 
negative manner [11-13]. The purpose of the following review is to discuss some of the general 
mechanisms  by  which  ECM  proteins  encourage  or  discourage  angiogenesis.  A  simplified 
illustration of ECM-endothelial cell interactions is given in (Fig.1). 
 
Extracellular matrix involvement in angiogenesis 
Many signaling pathways are involved in the process of angiogenesis. Some are much 
better  understood  than  others  and  possess  more  evidence  supporting  ECM  involvement  in 
angiogenesis.  The  pathway  most  unambiguously  regarded  as  involving  the  ECM  is  that  of 
integrin receptor binding [14]. Integrins exist as heterodimers on the cell surface, consisting of 
one  alpha  and  one  beta  subunit.  This  heterodimeric  arrangement  has  been  observed  in  C. 
elegans,  although  the  number  of  possible  alpha/beta  receptor  combinations  is  considerably 
smaller than in more complex animals as they possess only two alpha and two beta chains [2]. 
When a protein ligand binds to  an integrin, the subunits  are ligated triggering the signaling 
cascade inside the cell. Many of the ligands known to be relevant to angiogenesis possess a 
distinct three amino acid sequence arginine-glycine-aspartic acid (RGD) that is necessary for 
binding to certain integrins. Several important integrins include α5β1 (fibronectin receptor), α6β1 
(laminin receptor), and αvβ3 (vitronectin receptor) (Fig 2B). Although recognized for binding a 
particular matrix protein, an integrin heterodimer can bind multiple ligands. For instance, αvβ3 
can bind fibronectin, thrombospondin, and osteopontin [14]. 
The Notch signaling pathway represents another mechanism by which ECM proteins can 
affect angiogenesis. Notch signaling is important for cellular development, differentiation, and 5 
adhesion. Cells may express one or more of the four known mammalian Notch receptors (Notch 
1-4). When bound by one of the five known ligands (Delta-like ligand 1, 3, 4, Jagged 1, 2) the 
intracellular domain of the Notch receptor is cleaved by γ-secretase. The intracellular domain is 
then released to the nucleus to regulate gene expression. The matrix proteins CCN3, MAGP-1, 
and MAGP-2 are all known to interact with Notch 1 [15-16]. Notch 1 interactions with MAGP-1 
and MAGP-2 result in the shedding of the receptor’s ectodomain [16]. In endothelial cells, the 
interaction  between  MAGP-2  and  Notch  1  suppresses  the  signaling  pathway  resulting  in  a 
decrease in angiogenesis [17]. MAGP-2 can induce the shedding of Jagged 1 (soluble Jagged 1), 
and can also interact with Jagged 2, and Delta-like ligand 1 (Dll-1) [18]. Thrombospondin-1 and 
thrombospondin-2 both interact with the receptor Notch 3 and the ligand Jagged 1, but only 
thrombospondin-2  enhances  the  interaction  between  the  receptor  and  ligand  [19-20].  An 
illustration of these interactions is also provided (Fig 2C). 
An intriguing mechanism employed by proteins of the ECM to reduce angiogenesis is the 
induction of endothelial cell apoptosis. There are multiple pathways utilized to induce apoptosis 
in endothelial cells (Fig 2A). Some ECM proteins inhibit proliferation by inducing endothelial 
cell  cycle  arrest,  ultimately  resulting  in  apoptosis.  The  collagen  XVIII  fragment  endostatin 
induces G1 arrest while the plasminogen fragment angiostatin disrupts the transition between 
G2/M [21-22]. The intrinsic pathway of apoptosis, in which internal signaling cascades from the 
mitochondria  mediate  cell  death,  is  also  targeted  by  several  ECM  proteins.  Angiostatin  can 
upregulate  p53  expression,  resulting  in  endothelial  cell  apoptosis  [23].  Endostatin  and 
thrombospondin-1 both upregulate the pro-apoptotic protein Bax while downregulating the anti-
apoptotic protein Bcl-2 [24-25]. Endostatin downregulates the anti-apoptotic protein Bcl-XL as 
well [24].  6 
The extrinsic pathway of apoptosis involves outside-in signaling via a receptor-ligand 
mediated pathway. One such receptor-ligand system is the Fas-Fas-L apoptosis pathway. In the 
extrinsic Fas-apoptosis pathway, the cell surface receptor Fas (CD95) is bound and aggregated 
by Fas ligand (Fas-L) existing as a membrane-bound ligand or as a multimeric soluble ligand. 
When activated, Fas triggers an intracellular signaling cascade by cleaving multiple caspases, 
ultimately leading to apoptosis. The cytoplasmic FLICE-like inhibitory protein (FLIP) can act as 
a  competitive  inhibitor  to  caspase-8,  preventing  apoptosis  from  occurring.  The  collagen  IV 
fragment  canstatin  induces  Fas-L  expression  in  endothelial  cells,  contributing  to  autocrine 
induction of apoptosis [26]. Similarly, angiostatin upregulates mRNA expression of Fas-L while 
downregulating the mRNA expression of the anti-apoptotic FLICE-like inhibitory protein (FLIP) 
[23]. 
In addition to the previous examples of direct ECM-endothelial cell interaction, several 
other well known angiogenesis pathways (e.g. Growth factor-Receptor tyrosine kinase, Wnt-
Frizzled, Hedgehog-Patched, Cytokine-Cytokine receptor, and Angiopoietin-Tie) may result in 
the  upregulation  or  downregulation  of  ECM  proteins  or  may  interact  with  the  pathways 
previously discussed. For example, TGF-β and bFGF can influence the expression of integrins 
and  integrin-receptor  tyrosine  kinase  (RTK)  co-activation  is  often  involved  in  triggering 
signaling cascades [11-13]. 
ECM protein discovery and pathway mapping are continuously illuminating the number 
of  known  ECM-endothelial  cell  interactions  with  regard  to  angiogenesis,  yet  many  of  these 
interactions remain unknown. More research is needed to address these questions if we are to 
treat the underlying causes of pathological angiogenesis. The second chapter presented herein 
elucidates a unique interaction between endothelial cells and lumican, an extracellular matrix 7 
protein believed to have a role in cancer. I will now discuss a brief history of the protein lumican 
as well as the contributions of my research to the understanding of this ECM-derived regulator of 
angiogenesis.  
 
Lumican 
The  Small  Leucine  Rich  Proteoglycan  (SLRP)  family  member  lumican  was  first 
identified in the stroma of the cornea as a regulator of corneal transparency via its organization 
of collagen fibrillogenesis [27]. The 37 kDa core protein of lumican consists of an 18 amino acid 
signal  peptide,  a  negatively  charged  N-  terminus  containing  conserved  cysteine  residues,  a 
middle region containing 11 leucine rich repeats (LRRs), and a C- terminal LRR “ear repeat” 
[28-31]. The protein can be glycosylated at four points with glycosaminoglycan (GAG) side 
chains and exists as a 55-57 kDa glycoprotein in many tissues [32]. The protein is also modified 
through the addition of keratan sulfate chains in the 50-100 kDa proteoglycan form seen most 
frequently in the cornea [32-33]. Lumican can be cleaved by several matrix proteases including 
MT1-MMP, MMP-12, and ADAMTS-4 [34-35]. Figure 3 illustrates many important domains 
and motifs of the lumican core protein (Fig.3). 
Lumican  is  best  understood  as  a  regulator  of  collagen  fibrillogenesis.  Given  the 
homology of lumican to other, better-described members of the SLRP family (e.g. Decorin and 
Fibromodulin), the protein is thought to have a banana-shaped appearance although this remains 
to be directly confirmed [31]. The convex side of the classic SLRP banana shape possesses the 
hydrophilic GAG side chains, which provide interfibrillar spacing via water retention, while the 
concave side is wide enough to come into contact with an individual collagen fiber [32]. The 
concave side of lumican shares a homologous collagen-binding domain with its closest relative 8 
fibromodulin: this domain is on LRR5-7 [36-37]. Indeed, both lum -/- and fmod -/- knockout 
mice lack appropriate collagen organization and possess non-uniformly sized collagen [38-39]. 
Studies  demonstrate  that  Cysteine  41  within  the  conserved  N-terminal  cysteine  region  is 
necessary  for  proper  packing  and  structure  of  collagen  fibrils  [29].  Additionally,  lum  -/- 
knockout mice exhibit corneal opacity and skin laxity [38]. Thus, lumican is essential for proper 
collagen organization and distribution. 
 
Lumican in Cancer 
Though first identified in the corneal stroma, lumican is now known to be expressed in a 
variety  of  tissue  types  including  heart,  lung,  intestine,  bone,  articular  cartilage,  pancreas, 
placenta, kidney, breast, brain, cervix, colon, liver, smooth muscle, and uterus [27-28, 33, 40-
44]. Lumican’s collagen organizing ability, and its relationship to decorin, created an interest in 
this protein’s role in cancer. Immunohistochemical (IHC) analysis of lumican expression has 
been reported in breast, pancreatic, colorectal, cervical, neuroendocrine, and lung carcinomas. 
Similarly, microarray and cell culture studies have highlighted trends in lum mRNA expression 
in various stages of these and other cancer types [41, 43-55]. 
The expression of lumican in breast cancer has been correlated with higher tumor grade, 
but also with smaller tumor volume [41, 50]. Many breast tumors exhibit a reduction in lumican 
expression [56]. However, the role of lumican may not always be protective as expression in 
invasive  ductal  breast  carcinoma  is  nearly  fivefold  greater  compared  to  normal  [51].  Such 
conflicting reports underscore the difficulty of establishing causation from correlative data. In 
pancreatic cancer, lumican commonly localizes to the alpha cells of islets as well as the lesions 
surrounding the cancer [45]. While the presence of lumican can be observed pancreatic stellate 9 
cells  of  the  tumor  stroma,  there  is  substantially  less  expression  in  the  actual  cancer  cells. 
However stromal expression of lumican in patients has been correlated with shorter survival time 
compared  to  patients  lacking  stromal  lumican  [45-46].  Colorectal  cancer  cells  and  adjacent 
fibroblasts and epithelial cells have been known to synthesize lumican [43]. The highest levels of 
lumican have been identified in colorectal cells infiltrating lymph follicles and at the invasive 
front of the tumor [57]. Expression of lumican in colorectal cancer cells has been correlated with 
deep tumor invasion, lymph node metastasis, and lower patient survival [57]. In squamous cell 
lung carcinoma, lumican is expressed more in the cancer cells than surrounding stroma and is 
correlated  with  greater  keratinization  and  vascularization,  but  in  adenocarcinoma,  lumican 
expression is greater in the stroma and is correlated with pleural invasion and larger tumor size 
[54].  For  many  forms  of  cancer,  no  immunohistochemical  (IHC)  data  have  been  collected. 
However, microarray analysis of mRNA expression levels allows for the correlation of lumican 
expression with distinct phenotypes. For example, microarray analysis of prostate tumors has 
demonstrated a reduction in lumican expression as the cancer cells progress from more benign to 
more malignant phenotypes [58-59].  
In spite of this substantial correlative evidence, none of these studies have directly tested 
a role for lumican in cancer. However, recent experimental cell biology studies have suggested 
several hypotheses for lumican’s function in cancer. The soft agar assay is an excellent analog 
for  the  formation  of  tumors  in  vitro.  Lumican  overexpression  in  multiple  cell  types  has 
consistently  resulted  in  reduced  soft  agar  colony  formation  [60-62].  Additionally,  cellular 
migration and invasion  are both  inhibited in melanoma cells  exposed to lumican  and LRR9 
(lumicorin) is sufficient to inhibit melanoma migration in vitro [30]. In a mouse model of tumor 
metastasis, lumican-overexpressing melanoma cells formed fewer lung nodules [63]. Lumican 10 
also reduces the growth of subcutaneous tumors, although the underlying mechanism remains to 
be elucidated [60, 62].  
Explanations  as  to  how  such  tumor  reduction  occurs  have  mostly  focused  on  direct 
cancer cell effects, such as reduction in overall proliferation and invasive potential. For instance, 
lumican’s binding to cell surface β1 integrin has been proposed as a mechanism for inhibiting 
melanoma cell proliferation [47]. However, other potential mechanisms may involve lumican’s 
interaction with other cells in the tumor stroma. One such interaction proposed is the reduction of 
angiogenesis to the tumor. Multiple lines of evidence support a role for lumican in the regulation 
of angiogenesis. Lumican is localized to the peripheral blood vessels in adult human lungs, the 
renal  artery,  and  the  thickened  intima  of  the  coronary  artery  [33,  64-65].  Functionally, 
endothelial cell expression of lumican increases during the resolution phase of angiogenesis in 
which  vascularization  ceases  and  the  vessel  returns  to  a  state  of  angiostasis  [66].  Not 
surprisingly, lum -/- fmod -/- knockout mice exhibit increased vascularization in the myocardium, 
suggesting  an  anti-angiogenic  role  for  the  protein  [39].  Our  previous  data  demonstrate  that 
lumican can reverse the pro-angiogenic affects of bFGF in Matrigel plug assays, highlighting its 
effectiveness as anti-angiogenic molecule [66]. 
To study the effects of lumican on cancer cells, we created stable polyclonal lumican-
overexpressing cell lines from murine fibrosarcoma (MCA102) and pancreatic cancer (Pan02) as 
well as empty vector control cell lines [67-68]. The cell lines were analyzed via soft agar growth 
assay,  invasion  assay,  and  proliferation  assay.  Intriguingly,  while  lumican  overexpression  in 
Pan02 cells increased invasiveness, decreased soft agar colony size, and increased proliferation, 
in MCA102 cells, lumican decreased invasiveness, increased soft agar colony size, and had no 11 
effect on proliferation, suggesting that lumican acts in a cell-specific manner with respect to its 
effects on cancer cell phenotype.  
We  created  subcutaneous  tumors  of  our  cell lines  in  syngenic  host  animals.  In  stark 
contrast to what is seen in vitro, the effect of lumican overexpression in MCA102 and Pan02 in 
vivo was remarkably consistent: lumican-overexpressing tumors were smaller. Closer analysis of 
the tumors revealed that lumican-overexpressing tumors also possessed a lower vascular density. 
Hence,  the  reduction  in  tumor  size  may  involve  a  reduction  in  angiogenesis  mediated  by 
lumican. Previous studies lead us to hypothesize that lumican might inhibit angiogenesis by 
promoting apoptosis in invading endothelial cells. 
Like several other ECM proteins, lumican may be able to induce apoptosis [62, 69-70]. 
Lumican  preferentially  binds  Fas-L.  Lumican  -/-  murine  embryonic  fibroblasts  (MEFs)  and 
corneal  fibroblasts  (CFs)  express  little  or  no  Fas  on  their  surface;  a  condition  reversed  by 
transfection with lumican [69-70]. MEFs from lum -/- mice express less of the pro-apoptotic p53 
and more G1/S cyclins while murine melanoma cells expressing lumican have inhibited cyclin 
D1 expression (causing cell cycle arrest) and increased expression of the pro-apoptotic Bax [62, 
70]. Hence, lumican can increase susceptibility to apoptosis in certain fibroblasts and cancer 
cells.  
No  research  has  directly  examined  the  potential  apoptotic  effects  of  lumican  on 
endothelial cells. Hence, we created a lumican-overexpressing cell line from the murine brain 
microvascular endothelial cell line MB114, as well as a control cell line [71]. Consistently, more 
MB114-Lum cells survived to produce colonies as compared to MB114-Neo cells when plated at 
low  density.  We  have  not  previously  observed  any  anti-proliferative  effect  of  lumican  on 12 
endothelial  cells,  suggesting  that  this  reduction  in  colony  formation  is  due  to  decreased 
survivorship [66].  
Endothelial  cells  overexpressing  lumican  also  demonstrated  a  greater  amount  of 
apoptosis  as  measured  by  caspase-3  cleavage  in  both  the  presence  and  absence  of  the  Fas-
activating antibody Jo-2 as compared to the control cells. Lumican-overexpressing cancer cells 
exhibited more or less apoptosis than their controls, dependent on cell type. Thus, indiscriminate 
apoptosis  is  an  unlikely  mechanism  for  our  observed  reduction  in  tumor  growth.  Control 
endothelial cells cultured in conditioned media from the cancer cell lines in the presence or 
absence of Jo-2 also exhibited an increased level of caspase-3 cleavage in conditioned media 
from lumican-overexpressing cells.  
Whole cell lysates from the cancer cell lines and the endothelial cell lines were collected 
and analyzed for the presence of Fas-L, Fas, and FLIP. Fas-L was detected in all cell lines and at 
higher levels in the cancer cell lines. This is in agreement with previous reports of tumor cells 
expressing Fas-L, possibly as a means of achieving immune privilege [72-77]. Surprisingly, in 
contrast  to  what  has  been  reported  in  murine  embryonic  fibroblasts  (MEFs)  and  corneal 
fibroblasts (CFs), endothelial cells overexpressing lumican do not have a greater amount of Fas 
receptor.  However,  lumican-overexpressing  endothelial  cells  do  appear  to  downregulate  the 
expression of the anti-apoptotic protein FLIP. Thus our current model supports a role for lumican 
in cancer that involves regulating FLIP expression in the invading endothelial cells as a means 
for exacerbating apoptosis, reducing angiogenesis and consequently tumor growth. 
More research is required to further explore many of the unanswered questions produced 
in our research. We have not yet demonstrated that reintroduction of FLIP into the MB114-Lum 
cell line would correct their susceptibility to apoptosis. Additionally, the vessels observed in the 13 
tumor sections appear different in structure between the lumican and neo tumors. Perhaps the 
vessels  in  the  lumican-overexpressing  tumors  have  a  more  normal  phenotype  than  that 
commonly  seen  in  cancer.  Less  leaky  vessels  are  often  established  via  the  recruitment  of 
pericytes and smooth muscle cells. Therefore, we would like to stain for markers of pericytes and 
smooth  muscle  cells  in  the  tumor  sections.  It  would  also  be  beneficial  to  stain  for  cleaved 
caspase-3 to determine if this co-localizes with the vasculature. Other future experiments include 
the creation of cell lines that express both lumican and a soluble form of Fas receptor (sFas) 
lacking  the  transmembrane  region.  Such  cell  lines  will  allow  us  to  test  the  hypothesis  that 
lumican triggers Fas-mediated apoptosis by binding Fas as the sFas should presumably interact 
with some of the secreted lumican. Finally, it should be possible to examine which region of the 
lumican protein actively induces apoptosis and determine if this region alone is sufficient. 
 
Zebrafish Angiogenesis: Gene Knockdown 
The  third  chapter  takes  the  first  steps  of  characterizing  potential  novel  regulators  of 
angiogenesis using anti-sense morpholinos in transgenic zebrafish. Zebrafish (Danio rerio) have 
been used as a model organism to study development for over fifty years [78]. Zebrafish are easy 
to maintain, develop rapidly in a nearly transparent system, and with nearly 80% of the D. rerio 
genome sequenced, researchers are increasingly utilizing zebrafish for genetic studies. Because 
they share many organs and possess similar genomes, zebrafish remain an excellent model for 
human conditions [79]. 
One can quickly screen through many gene targets utilizing a gene knockdown approach. 
The targeting reagent used should be relatively stable in the zebrafish embryo and specific for a 
particular target. One class of gene targeting reagent is anti-sense morpholino oligonucleotides 14 
[80]. Morpholinos are similar in structure to  DNA but possess morpholine rings rather than 
deoxyribose. Their increased stability makes them ideal for studying targeted gene knockdown 
within the first five days of zebrafish development. Although the morpholinos are specific for 
their target genes, the effects of these knockdowns may not be specific. Occasionally, observed 
phenotypes are the result of non-specific apoptosis. Thus co-injection of zebrafish embryos with 
a specific target morpholino and an anti-p53 morpholino can be utilized to determine if some of 
the developmental defects associated with the specific target morpholino are due to nonspecific 
induction of apoptosis [81].  
The study of neovascularization has been pursued in the zebrafish as well. In 2003, a 
transgenic line was created that expresses GFP under the blood vessel-specific fli1 promoter. 
These Tg(fli1:EGFP) zebrafish could be observed under fluorescence to study the development 
of the blood vasculature [82]. In that same year, another group created a transgenic line that 
expresses dsRed under the erythrocytic gata1 promoter [83]. When crossed, these fish could be 
studied under fluorescence in the development of blood vessels (GFP) and the development of 
red blood cells (dsRed). Previous research supports the potential for success using this transgenic 
model. 
Embryos are collected in the 1-2 cell stage and injected with the desired morpholino in a 
vehicle of phenol red. Typically 4 ng of morpholino are delivered to each embryo, although more 
may be required to produce an observable phenotype. No more than 12 ng are injected. If 4 ng 
results in an observable phenotype, then lower doses are utilized until a minimally sufficient 
dose can be found. However, typically no less than 0.5 ng are injected. Sham injections of equal 
volume of empty vehicle are used to  create  control  fish. When a target  has  been shown to 
produce a vascular phenotype, p53 morpholino is co-injected to verify vascular specificity. Fish 15 
are  observed  on  the  following  days  to  compare  morphological  differences  in  the  sprouting 
intersegmental vessels (ISV) between control and test fish.  
 
Knockdown targets that are potential regulators of angiogenesis 
Choosing the proper target for morpholino knockdown is essential for discovering likely 
regulators  of  angiogenesis.  Previously,  we  performed  microarray  experiments  on  mRNA 
extracted from tubulating MB114 endothelial cells at 1hr, 5hr, 15hr, and 25hr [84]. Our results 
confirmed the differential regulation of known angiogenic genes. More importantly, many novel 
gene targets were also found to be differentially regulated. Several of these targets were assessed 
via reverse transcription (RT) PCR and their patterns of regulation during the different time 
points  were  found  to  be  in  agreement  with  the  patterns  observed  in  the  microarray.  Of  the 
substantial list of targets identified, I have chosen four that are secreted matrix proteins which are 
potential regulators of angiogenesis. These four genes include the upregulated clu (clusterin), 
grm (gremlin-1), and serpine2 (serpinE2), as well as the downregulated npnt (nephronectin).  
Clusterin (apolipoprotein J) has been implicated in a variety of cancers, including renal 
cell cancer, colorectal cancer, and endometrial carcinoma [85-87]. Expression of clusterin in 
melanoma  is  correlated  with  increased  malignancy  but  is  only  upregulated  in  a  minority  of 
melanomas  [88-89].  In  hepatocellular  carcinoma,  clusterin  expression  results  in  a  more 
aggressive phenotype and might function in metastasis [90-91]. However, in non-small cell lung 
cancer, cytoplasmic clusterin expression may promote patient survival [92]. In prostate cancer, 
clusterin is downregulated and may reduce cancer cell proliferation and migration [93-94]. In 
many cases clusterin is thought to make cancer cells chemoresistant by acting as a pro-survival 
factor in its cytoplasmic form. Anti-sense oligonucleotides to clusterin have been researched as a 16 
means  to  combat  this  effect  in  cancer  cells.  In  the  endothelial  cell  line  HUVEC,  anti-sense 
oligonucleotides to clusterin inhibit growth and angiogenesis, while promoting apoptosis [95]. 
However,  clusterin  expression  is  also  increased  in  tissues  affected  by  Fuchs’  Endothelial 
Dystrophy  (FED),  a  syndrome  marked  by  increased  apoptosis  [96].  In  the  microarray 
experiment, clusterin was upregulated 6.6 fold over the 25 hr timecourse [66]. 
Gremlin-1 (Drm) is a bone morphogenic protein (BMP) antagonist overexpressed in a 
variety of cancers including sarcoma, ovarian, breast, colon, pancreatic, lung and cervical cancer, 
and is associated with increased growth stimulation and telomerase activity [97]. Hypoxia can 
drive the expression of gremlin-1 and it is highly expressed in the endothelial cells of lung tumor 
vasculature  [98-99].  Additionally,  gremlin-1  is  believed  to  play  a  role  in  the  aberrant 
angiogenesis  observed  in  endometriosis  [100].  In  the  microarray  experiment,  gremlin-1  was 
upregulated 3.9 fold over the 25 hr timecourse [66]. 
Nephronectin (POEM) was first identified as a binding partner to integrin α8β1 in the 
human  embryonic  kidney  [101].  Although  nephronectin  has  been  localized  to  the  tumor 
epithelium of highly metastatic breast tumors, it increases melanoma cell adhesion in vitro and 
reduces invasion and migration [102-103]. During zebrafish development nephronectin regulates 
the spatial expression of BMP4 required for proper heart development [104]. In the microarray 
experiment, nephronectin was downregulated 0.2 fold over the 25 hr timecourse [66].  
SerpinE2  (Protease  nexin-1  (PN-1))  is  strongly  expressed  in  oral  squamous  cell, 
pancreatic, gastric, and colorectal cancers as well as the metastatic subclone of the pancreatic 
cancer cell line SUIT-2 [105-106]. SerpinE2is believed to increase invasion of cancer cells by 
altering the production of matrix proteins and may regulate uPA-mediated cancer cell migration 17 
and  metastasis  in  breast  cancer  [105,  107].  In  the  microarray  experiment,  serpinE2  was 
upregulated 29.5 fold over the 25 hr timecourse [66]. 
Although this project is still in its infancy, we have data suggesting that most of these 
targets  are essential  for  vascular development,  with  one exception. Increasing doses of anti-
clusterin  morpholino  (up  to  12  ng)  had  no  apparent  effect  on  zebrafish  development: 
morpholino-treated  fish  were  indistinguishable  from  vehicle-injected  controls.  Conversely, 
embryos treated with 4 ng anti-gremlin-1 morpholino had a less-developed vasculature compared 
to controls at 1 day. Treatment with 4 ng anti-serpinE2 was lethal in the majority of fish tested. 
The one surviving fish possessed underdeveloped vasculature at day 1 as compared to controls. 
Future work will involve determining the lowest effective doses of these morpholinos. Injection 
with  as  little  as  1  ng  anti-nephronectin  morpholino  resulted  in  delayed  vascularization  as 
compared to  control  fish. Co-injection  of each of the three effective morpholinos  with  anti-
p53morpholino is required to confirm vascular specificity. Validated targets will ultimately be 
overexpressed in a cell culture model to further characterize the effects obtained in a gain-of-
function cell system. 
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Figure 1. Common interactions between proteins of the extracellular matrix and endothelial cells 
ECM proteins interact with endothelial cells via Integrin, Notch, and Apoptosis signaling 
pathways. Several non-matrix interactions are also listed. (RTK- Receptor tyrosine kinase, 
MAPK- Mitogen-activated protein kinase, Ang- Angiopoietin, TGF-β- Transforming growth 
factor- β, VEGF- Vascular endothelial growth factor, FGF- Fibroblast growth factor, EGF- 
Epidermal growth factor.)19 
 
Figure 2. Specific interactions of known extracellular matrix proteins with endothelial cells 
A)  The  extracellular  matrix  (ECM)  proteins  canstatin,  angiostatin,  endostatin,  and 
thrombospondin-1 can all influence endothelial cell apoptosis. B) Many ECM proteins, such as 
fibronectin,  laminin,  and  vitronectin  attach  to  endothelial  cells  via  integrin  receptors  on  the 
cellular surface. In some cases, co-activation of receptor tyrosine kinases (RTK) also occurs. C) 
The ECM proteins  CCN3, MAGP-1, MAGP-2, and thrombospondin-1 mediate  Notch/ligand 
interactions between endothelial cells.  
 
Figure 3. Lumican motifs and domains 
An illustration of known motifs and domains of importance within the protein lumican. 
20  21 
 
 
 
CHAPTER 2 
 
LUMICAN REDUCES TUMOR GROWTH VIA INDUCTION OF FAS-MEDIATED 
ENDOTHELIAL CELL APOPTOSIS 
Abstract 
To study the effects of lumican on cancer cells, we create stable polyclonal lumican-
overexpressing cell lines from murine fibrosarcoma (MCA102) and pancreatic cancer (Pan02). 
Intriguingly, while lumican overexpression in Pan02 cells increased invasiveness, decreased soft 
agar colony size, and increased proliferation, in MCA102 cells, lumican decreased invasiveness, 
increased soft agar colony size, and had no effect on proliferation. In stark contrast to these in 
vitro results,  the effect  of  lumican  overexpression in  MCA102 and Pan02  cells  in  vivo  was 
remarkably consistent: lumican-overexpressing tumors were smaller. Closer analysis of revealed 
that these lumican-overexpressing tumors also possessed a lower vascular density. As is the case 
for several other ECM proteins, previous work suggests that lumican may induce apoptosis; 
hence we examined this potential role in the tumor cell lines and the murine brain microvascular 
endothelial cell line MB114. In MB114 endothelial cells, the presence of lumican increased the 
amount of apoptosis as measured by caspase-3 cleavage in both the presence and absence of the 
Fas-activating  antibody  Jo-2.  Pan02  cells  overexpressing  lumican  were  also  affected  in  this 
manner,  however  MCA102  cells  were  not.  Thus,  indiscriminate  apoptosis  is  an  unlikely 
mechanism  for  our  observed  reduction  in  tumor  growth  as  this  apoptotic  effect  was  not 22 
generalized. In contrast to what has been reported in murine embryonic fibroblasts and corneal 
fibroblasts, endothelial cells overexpressing lumican do not have more Fas expression. However, 
lumican-overexpressing endothelial cells had reduced anti-apoptotic FLIP (FLICE-like inhibitory 
protein)  expression.  Thus  our  current  model  supports  a  role  of  lumican  in  cancer  of 
downregulating  FLIP  expression  in  the  invading  endothelial  cells  as  a  means  for  reducing 
angiogenesis and consequently tumor growth. 
 
Introduction 
The extracellular matrix has garnered much attention in the last two decades, due in large 
part to the discovery of constituent proteins that interact with both structural elements such as 
collagen as well as with membrane-bound receptors on the surface of cells. These “matrikines,” 
as these matrix constituents are now called, can play important roles in regulating signaling 
pathways including those involved in tumorigenesis and angiogenesis [108]. Members of the 
small  leucine-rich  proteoglycan  (SLRP)  family  have  been  extensively  studied  for  both  their 
ability  to  bind  collagen  and  other  matrix  proteins,  and  their  ability  to  perform  outside-in 
signaling  [28].  The  best  characterized  members  of  the  SLRP  family  include  decorin, 
fibromodulin, and lumican. The latter of these proteins is our focus as it is the least understood. 
Lumican is a 338 amino acid member of the SLRP family that exists as a 50-100 kDa 
keratan sulfate proteoglycan in the cornea but exists as a 55-57 kDa glycoprotein in most other 
tissues [28, 33]. The 37 kDa core protein possesses a middle region containing 11 leucine rich 
repeats (LRRs), and a C- terminal  LRR “ear repeat”  arranged in a “banana-shaped” tertiary 
structure [31]. Lumican was originally identified as a regulator of collagen fibrillogenesis and the 
concave side of lumican shares  a homologous  collagen-binding domain on  LRR5-7 with  its 23 
closest relative fibromodulin, another collagen regulator [36]. Indeed, both lum -/- and fmod -/- 
knockout mice lack appropriate collagen organization [38-39, 109]. Proper collagen organization 
is vital to establishing corneal transparency (for which lumican derives its namesake) and lum -/- 
mice  appropriately  exhibit  corneal  opacity  [27,  38].  Studies  examining  SLRPs  and  their 
involvement in cancer have mostly focused on decorin, but the role of the SLRP family member 
lumican in cancer is receiving increasing attention [41, 43-49, 110-112]. 
There  is  substantial  work  implicating  lumican’s  involvement  in  cancer. 
Immunohistochemical (IHC) analysis of lumican expression has been reported in melanoma and 
osteosarcoma  as  well  as  in  breast,  pancreatic,  colorectal,  cervical,  neuroendocrine,  and  lung 
carcinomas. Similarly, microarray studies have highlighted trends in lum mRNA expression in 
various  stages  of  these  and  other  cancer  types  [41,  43-55].  At  best,  these  methods  provide 
correlative data for the presence or absence of lumican and the severity of disease, but they do 
not elucidate the role of lumican in cancer. More information has been gleaned on the role of 
lumican  in  cancer  from  experimental  cell  biology.  For  example,  lumican-overexpression 
consistently  results  in  reduced  colony  formation  in  anchorage-independent  soft  agar  growth 
assays  [60-62].  Additionally,  melanoma  cells  exhibit  decreased  migration,  invasion,  and 
metastasis  when  treated  with  lumican  [62-63].  Lumican  also  results  in  a  reduction  in 
subcutaneous tumor volume in mouse models, possibly by reducing angiogenesis [60, 62]. 
Multiple  lines  of  evidence  support  a  role  for  lumican  in  the  regulation  of  vascular 
function. For example, lumican is localized to the peripheral blood vessels in adult human lungs 
and  to  the  thickened  intima  of  the  coronary  artery  [33,  64].  Functionally,  endothelial  cell 
expression  of  lumican  increases  during  the  resolution  phase  of  angiogenesis  in  which 
vascularization ceases and the vessel returns to a state of angiostasis [66]. Similarly, lumican is 24 
strongly expressed in the resting endothelium of the renal vein [65]. Not surprisingly, lum -/- 
fmod -/- knockout mice exhibit increased vascularization in the myocardium, suggesting an anti-
angiogenic role for lumican [39]. Finally, our previous data demonstrate that lumican can reverse 
the pro-angiogenic affects  of  basic fibroblast  growth factor (bFGF) in  Matrigel plug assays, 
highlighting lumican’s effectiveness as an anti-angiogenic molecule [66]. 
Our goal in the present study was to determine what effect lumican overexpression has on 
cancer cells in vitro and in vivo, and the potential mechanism(s) of these effects. Specifically, we 
test the hypothesis that lumican plays an anti-angiogenic role in the tumor microenvironment. 
We  demonstrate  that  overexpression  of  lumican  in  the  murine  models  for  fibrosarcoma 
(MCA102) and pancreatic cancer (Pan02) resulted in pleiotropic in vitro effects on invasion, 
proliferation, and soft agar colony formation [67-68]. In a subcutaneous tumor model in syngenic 
mice, lumican overexpression consistently resulted in reduced tumor volume and lower blood 
vessel density. Furthermore, lumican increased MB114 endothelial cell susceptibility to Fas-
induced apoptosis, reduced survival, and downregulated the anti-apoptotic FLICE-like inhibitory 
protein  (FLIP)  [71].  Together,  these  results  support  a  model  in  which  lumican  enhances 
apoptosis of endothelial cells as they invade the tumor stroma during angiogenesis, possibly via 
regulating FLIP expression. 
 
Materials and Methods 
Cell culture, plasmids, and retroviral infections 
The full length murine lumican cDNA (#5707371) less the secretory signal was cloned 
into pSecTag A plasmid with Myc-His6 appended to the 3’end via the 5’BamHI and 3’ NotI 
restriction sites (fwd 5’-GGCGGCGGATCCCAATACTACGATTATGAC-3’) (rev 5’-25 
GGCGGCGCGGCCGCGTTAACGGTGATTTCATT-3’). The resulting Igκ-Lumican-Myc-His6 
cassette was ligated into the bicistronic retroviral vector pMSCV-Neo via the 5’HpaI and 3’ 
BglII restriction sites (fwd 5’-CCGGCCGAATTCTTAATACGACTCACTATAGGG-3’) (rev 
5’-CCGGCCAGATCTCAACAGATGGCTGGCAACTAG-3’). Retroviral supernatants were 
produced by EcoPack2 retroviral packaging cells (Clontech, USA) and used to infect the murine 
fibrosarcoma cell line MCA102, murine pancreatic carcinoma cell line Pan02, and the murine 
brain microvascular endothelial cell line MB114 as described previously [113]. Cells were 
selected via addition of 400 nM Neomycin and maintained with 200 nM Neomycin. 
Detection  of  endogenous  lumican  was  achieved  via  TCA  50%/DOC  .01%  protein 
precipitation  from  conditioned serum free media (SFM)  and confirmation  of myc-his-tagged 
lumican  overexpression  was  achieved  via  Ni-NTA  Agarose  (Qiagen,  Valencia,  CA)  binding 
from conditioned serum free media. 
 
In vitro cancer cell assays 
The  effect  of  lumican  overexpression  on  MCA102  and  Pan02  cellular  invasion  was 
measured  using  a  modified  Boydenchamber  assay  as  described  previously  [114].  Briefly,  a 
porous membrane (8 µm pore, 24-well format; BD Biosciences, San Jose, CA) was coated with 
100 µl of a 1:50 dilution of Matrigel (BD Biosciences, San Jose, CA) which was allowed to dry 
overnight at room temperature. The following day, 100,000 control and lumican-overexpressing 
cells were cultured on dried membranes in SFM +.1% BSA. Cellular invasion was induced by 
adding  5%  serum  to  the  lower  chamber  and  was  allowed  to  proceed  at  37º  C  for  48  h. 
Subsequently, Matrigel-invading cells were washed twice with ice-cold PBS and immediately 
fixed for 10 min with 95% ethanol. Cells remaining in the upper chamber were removed with a 26 
cotton swab, whereas those remaining in the lower chamber were stained with crystal violet. 
Invasion was measured by densitometry utilizing the software ImageJ (NIH, Bethesda, MD). 
The ability of lumican to alter the anchorage-independent growth of MCA102 and Pan02 
cells was performed as described previously [115]. Briefly, 2 ml of a 1.2% agarose mixture in 
DMEM  were  allowed  to  solidify  in  6-well  plates.  Control  or  lumican-overexpressing  cells 
(50,000 cells/well) were diluted with an equal amount of DMEM-agarose mixture and allowed to 
solidify before placing in 37º C for 24 h. Plates were observed and 1 ml DMEM+ 10% FBS was 
added to each well as needed to avoid drying out. Colony areas were measured after 30 days 
using the software NIS-Elements D 3.00 SP1 (Build 455) (Nikon, Inc., Melville, NY). 
Cell proliferation assays were conducted with WST-1 (Clontech, Mountain View, CA). 
Briefly, 500 cells were placed in 100 µl complete media in 12 wells of a 96-well plate and 
allowed to grow at 37º C for 24 h. The following day, the first three wells were replaced with 
100 µl complete media containing 10 µl WST-1. Empty wells were also treated to establish a 
blank baseline. After four hours, wells were measured at OD 450nm to determine proliferation. 
This procedure was followed for each of four days to determine the proliferation rates for the 
control and lumican-overexpressing cells. 
 
In vivo tumor growth studies 
Control  and  lumican-overexpressing  MCA102  and  Pan02  cells  were  resuspended  in 
sterile phosphate buffered saline (PBS) and injected subcutaneously at a density of 1,000,000 
cells/ 100 µl injection between the shoulder blades of 10-week-old male C57BL/6 mice (three 
mice per condition; Jackson Laboratories, Bar Harbor, ME). Mice were monitored daily and 
primary  tumors  were  measured  with  calipers  between  days  9  and  17.  Tumor  volumes  were 27 
calculated using the following equation: Volume = (d
2 x D)/2, where D is the long side and d is 
the short side. After 17 days (or if tumors became necrotic or achieved a size greater than 2000 
mm
3) mice were killed and their primary tumors were excised and weighed. Animal studies were 
performed  in  accordance  with  the  animal  protocol  procedures  approved  by  the  Institutional 
Animal Care and Use Committee of Indiana State University (protocol #1-19-2008AA). 
 
Immunohistochemistry 
Excised tumors were fixed in 4% paraformaldehyde for 1 hr and placed in 70% ethanol 
before paraffin embedding and sectioning following standard procedure [116]. Sections were 
prepared  via  hematoxylin  and  eosin  staining  and  additional  sections  were  probed  with  anti-
mouse CD31 in the Clarian Pathology Laboratory at Indiana University (Indianapolis, IN). 
 
Apoptosis assays 
The effect of lumican on endothelial cell apoptosis was assessed by measuring caspase-3 
cleavage  upon  extended  treatment  with  an  apoptosis-inducing  agent.  Approximately  50,000 
Lumican-overexpressing or control MB114 cells were plated onto 12-well culture plates. Cells 
were allowed to grow 24 h before washing with PBS and treating with 1 ml of serum free media 
(SFM) in the presence or absence of the hamster anti-mouse CD95 (Fas) agonizing antibody Jo-2 
(final concentration 1 µg/ml) (554254; BD Pharmingen, San Jose, CA). To examine the effect of 
lumican conditioned media on endothelial cells, media isolated from lumican-overexpressing or 
control MCA102 or Pan02 cells was filtered and buffered with 10mM pH 7.3 HEPES buffer. 
MB114 control cells were grown in the presence of each conditioned media in the presence or 28 
absence of Jo-2. After 48-72 h live and dead cells were lysed in 1x SDS-loading buffer, and 
assayed via western blot. 
 
Colony forming survival assays 
The  survival  ability  of  lumican-overexpressing  endothelial  cells  was  compared  to 
controls in the following manner. Five hundred MB114-Neo and MB114-Lum cells were plated 
onto 6 cm plates containing 4 mL MB114 media. Cells were allowed to adhere and grow for 
approximately 1 week until colonies were visible by eye. Media was removed and plates were 
washed with 1 x PBS. Cells were fixed with 95% ethanol for five minutes and stained with 
crystal violet stain. Excess stain was removed with water and plates were allowed to dry before 
scanning and densitometry utilizing the software ImageJ.  
 
Western Blot 
Western blotting was performed as described previously [114]. Antibodies utilized in the 
experiments include the following: mouse anti-c-Myc (1:1000) (9E10, MMS-150R) (Covance, 
Inc., Princeton, NJ); mouse anti-β-actin (1:1000) (sc-47778), rabbit anti-Fas-L (1:500) (C-178, 
sc-6237), rabbit anti-Fas (1:500) (A-20, sc-1023) (Santa Cruz Biotechnology, Santa Cruz, CA); 
rabbit  anti-FLIP  (1:500)  (#3210),  rabbit  anti-caspase-3  (1:500)  (#9662)  (Cell  Signaling 
Technology,  Inc.,  Danvers,  MA);  rabbit  anti-lumican  (1:100)  (kindly  provided  by  Dr.  S. 
Chakravarti,  Johns  Hopkins  University,  Baltimore,  MA);  and  sheep  anti-mouse  (1:5000) 
(NA931-1ML), donkey anti-rabbit (1:5000) (NA934-1ML) (GE Healthcare, Piscataway, NJ). 
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Results 
Lumican overexpression exhibits pleiotropic effects on MCA102 murine fibrosarcoma cells and 
Pan02 murine pancreatic cancer cells in vitro  
  The MCA102 fibrosarcoma and Pan02 pancreatic cancer cell lines were transduced with 
retroviral constructs encoding either murine lumican cDNA to which a C-terminal Myc-epitope 
had been appended or an empty vector. Neomycin selection was subsequently used to establish 
stable  polyclonal  cell  lines.  Conditioned  media  from  these  cell  lines  were  precipitated  with 
TCA/DOC.  Western  blotting  with  the  anti-Myc  antibody  confirmed  the  overexpression  of 
lumican in the stably selected cell lines (Fig. 1). Furthermore, western blotting with the anti-
lumican antibody  revealed an undetectable level of endogenous lumican expression in either 
MCA102 or Pan02 cell lines (Fig. 1). Due to the deficit of direct evidence regarding the role of 
lumican  in  cancer,  we  subjected  the  lumican-overexpressing  MCA102  and  Pan02  cells 
(MCA102-Lum and Pan02-Lum) and their control counterparts (MCA102-Neo and Pan02-Neo) 
to a variety of in vitro experiments designed to mimic several aspects of tumor behavior.  
Tumor  cell  invasion  is  one  of  the  deadliest  aspects  of  cancer  as  the  ability  to 
enzymatically degrade a collagen matrix is correlated with metastatic potential [117]. Thusly, 
Boyden  chamber  invasion  assays  were  performed  to  assess  the  ability  of  lumican  to  affect 
invasion  through a Matrigel  matrix.  Lumican  overexpression resulted in  a 22% reduction  in 
invasion in the MCA102 cells, but enhanced invasion in the Pan02 cells by 91% (Fig. 2A,B).  
Cancer cells have the unique ability to form colonies in soft agar, as they do not require 
anchorage via an extracellular substrate to grow. As this is an excellent in vitro analog for tumor 
formation,  we  performed  soft  agar  assays  to  determine  if  lumican  overexpression  affects 
anchorage-independent growth of cancer cells. In contrast to the results obtained in the invasion 30 
assays, lumican overexpression increased the average colony size of MCA102 cells 38%, but in 
Pan02 cells the average colony size was reduced 36% (Fig. 2C,D).  
A hallmark of cancer cells is their rapid rate of proliferation. To monitor the effect of 
lumican on cancer proliferation, we used WST-1 proliferation assays to determine if lumican 
overexpression influences the growth rate of cancer cells. Similar to the results of the invasion 
assay, lumican overexpression significantly increased the proliferation of Pan02 cells (Fig. 2F). 
However, lumican overexpression had no detectable effect on MCA102 cell proliferation (Fig. 
2E).  
Collectively, these in vitro data indicate that the overexpression of lumican in these tumor 
cell  lines  resulted  in  no  consistent  pattern  of  effects  on  the  various  tumor  cell  activities  of 
invasion, proliferation, or anchorage-independent growth between the two cell lines. From this 
data we were unable to arrive at a conclusive effect of lumican on cancer cells, however in vitro 
data is removed from the complex microenvironment of the host organism and may not reflect 
the behavior of the cancer in vivo. In particular, our previous data suggest that lumican is an 
inhibitor of angiogenesis [66]. In light of this, we next sought to determine what effect lumican 
would have in an animal model of tumor growth. 
 
Lumican  overexpression  consistently  reduces  MCA102  murine  fibrosarcoma  and  Pan02 
pancreatic cancer tumor volume in syngenic mice 
Understanding  the  effect  of  lumican  in  cancer  requires  consideration  of  the 
microenvironment established by complex interactions between the host and the cancer cells. To 
determine how lumican-overexpressing cancer cells would interact with a syngenic host, we 
injected male C57BL/6 mice subcutaneously with equal numbers of MCA102-Lum, MCA102-31 
Neo,  Pan02-Lum,  or  Pan02-Neo  cells.  Tumor  growth  curves  and  final  tumor  masses  both 
indicate that lumican overexpression results in an approximately 60% reduction in mean tumor 
volume for both MCA102 and Pan02 cells (Fig. 3A,B). This is in stark contrast to the in vitro 
data which demonstrated inconsistent effects on invasion, proliferation,  and soft agar colony 
formation.  Previously,  we  have  demonstrated  lumican  can  reduce  blood  vessel  growth  into 
Matrigel plugs [66]. Such a reduction might explain the reason for the smaller average tumor 
volume via a reduction in angiogenesis. We therefore examined blood vessel density within the 
extracted tumors. 
 
Tumors overexpressing lumican possess reduced vasculature 
Vascular density in the tumors was determined using hemotoxylin and eosin staining 
followed by counting the number of vessels in each of 10 fields of each tumor section at 200x 
magnification.  MCA102-Lum  tumors  averaged  62%  fewer  vessels  per  field  compared  to 
MCA102-Neo  tumors.  Similarly,  Pan02-Lum  tumors  averaged  43%  fewer  vessels  per  field 
compared to Pan02-Neo tumors (Fig. 4A).  In addition to hemotoxylin, tumor sections were 
stained for the endothelial cell marker CD31. Again, the lumican-overexpressing tumors had a 
lower vascular density compared to the control tumors (Fig. 4B).  
Previous research suggests that lumican may mediate Fas-Fas-L interactions, contributing 
to  induction  of  apoptosis;  an  established  mechanism  for  the  reduction  of  angiogenesis  by 
extracellular matrix molecules [62-63, 69-70]. Based on these previous findings, we sought to 
determine what effect, if any, lumican has on the induction of apoptosis in MCA102, Pan02, and 
MB114 cells. 
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Lumican increases apoptosis in endothelial cells 
To determine if lumican could facilitate apoptosis in endothelial cells, we first established 
lumican-overexpressing and control MB114 endothelial cell lines and confirmed overexpression 
via western blot (Fig. 5A). Once again, western blot analysis with the anti-lumican antibody 
revealed that lumican was undetectable in control cells but readily apparent in the conditioned 
media of MB114-Lum cells.  
Consistent with a role in promoting apoptosis, 37% fewer MB114-Lum cells survived to 
form colonies when plated at a low density as compared to MB114-Neo cells (Fig. 5B,C). We 
have not previously noted an effect on proliferation associated with lumican in endothelial cells 
[66]. Thus, we investigated the possibility that lumican promotes endothelial cell apoptosis. 
In the extrinsic Fas-apoptosis pathway, the cell surface receptor Fas (CD95) is bound and 
aggregated  by  Fas  ligand  (Fas-L)  existing  as  a  membrane-bound  ligand  or  as  a  multimeric 
soluble  ligand.  When  activated,  Fas  triggers  an  intracellular  signaling  cascade  by  cleaving 
multiple  caspases,  ultimately  leading  to  apoptosis.  The  cytoplasmic  FLICE-like  inhibitory 
protein  (FLIP)  can  act  as  a  competitive  inhibitor  to  caspase-8,  preventing  apoptosis  from 
progressing.  
MB114-Lum and MB114-Neo cells were cultured in the presence or absence of the Fas-
activating antibody Jo-2 under serum free conditions. After 48-72 hr, live and dead cells were 
collected and Fas apoptosis was assessed via immunoblotting for cleaved caspase-3. Blots were 
subsequently  stripped  and  reblotted  with  anti-βactin  to  monitor  protein  loading.  Lumican-
overexpressing MB114 cells demonstrated a greater amount of cleaved caspase-3 than control 
cells in both untreated conditions and upon treatment with Jo-2 (Fig. 5B). Interestingly, while 
lumican overexpression did appear to increase apoptosis in Pan02 cells in the presence of Jo-2, it 33 
lacked this effect in MCA102 cells (Fig. 5B). This is particularly interesting as our in vitro data 
demonstrated consistently greater proliferation and invasion in the Pan02-Lum cell line. As no 
increase  in  apoptosis  was  observed  in  the  MCA102-Lum  cell  line,  an  overall  increase  in 
susceptibility to apoptosis is an unlikely mechanism for the reduction in tumor size observed in 
the mice. To mimic the conditions of the animal study, MB114 control cells were treated with 
conditioned media from MCA102-Lum, MCA102-Neo, Pan02-Lum, or Pan02-Neo cells. Prior 
to applying the conditioned media, we confirmed that MCA102-Lum and Pan02-Lum media 
expressed  lumican  while  their  control  media  did  not  (Fig.  5C).  Consistent  with  the 
overexpression  results,  MB114-Neo  cells  treated  with  the  lumican  conditioned  media  in  the 
presence or absence of Jo-2 possessed more cleaved caspase-3 activity than those treated with 
control conditioned media (Fig. 5D).  
To investigate the mechanism by which lumican promotes apoptosis, we assessed the 
relative amounts of proteins known to affect apoptosis within the MCA102, Pan02, and MB114 
control and lumican-overexpressing cell lines. Previous reports have demonstrated that lum -/- 
murine embryonic fibroblasts and corneal fibroblasts possess little or no Fas receptor and that 
transfection with lumican can restore this to wild-type level  [69-70]. However, our analysis of 
MB114,  MCA102,  and  Pan02  cell  lysates  from  lumican-overexpressing  and  control  cells 
revealed  that  the  level  of  Fas  receptor  remained  static  (Fig.  5E).  Expression  of  Fas-L  was 
determined to be slightly higher in MCA102 and Pan02 cells, but it was also present in MB114 
cells; however, there was no difference in expression between control cells and those expressing 
lumican  (Fig.  5E).  Interestingly,  expression  of  the  anti-apoptotic  protein  FLIP  (FLICE-like 
inhibitory protein) was reduced in the lumican-overexpressing MB114 cells compared to control 
cells. (Fig. 5E).  34 
Discussion 
Much  of  our  current  understanding  of  lumican  in  cancer  is  derived  from 
immunohistochemical  correlations  of  the  relative  abundance  of  the  protein  in  the  stroma  of 
cancerous and noncancerous tissues. Our hypothesis-driven approach illuminates a functional 
role of lumican in  tumor growth.  In this  study, we demonstrated that  overexpression of the 
extracellular matrix protein lumican has differential effects on cancer cell proliferation, invasion, 
and anchorage independent growth in the fibrosarcoma cell line MCA102 and the pancreatic 
cancer  cell  line  Pan02.  Despite  the  pleiotropic  in  vitro  effects,  lumican  overexpression 
consistently  reduced  tumor  size  and  blood  vessel  density  in  vivo.  Furthermore,  we  provide 
evidence that this reduction in blood vessel density is due to a pro-apoptotic effect of lumican on 
the endothelial cells invading the tumor stroma. 
The results of our in vitro analyses on MCA102 and Pan02 cells overexpressing lumican 
demonstrate the cell-specific effects  of lumican  on  several deadly aspects  of cancer  without 
regard to the host microenvironment. Pan02 cells overexpressing lumican were more invasive in 
Matrigel-coated Boyden chamber invasion assays than their control counterparts. The opposite 
effect was observed in MCA102, which exhibited a marked reduction in invasion. Soft agar 
assays were performed to assess lumican’s effect on anchorage independent growth. Lumican 
overexpression  resulted  in  smaller  average  colony  size  in  MCA102.  Past  experiments  on  a 
variety of cell lines support the notion that lumican reduces the size of soft agar colonies [60-62]. 
However this pattern was not observed in Pan02, in which lumican overexpression resulted in 
increased  colony  size.  We  assessed  the  effect  lumican  overexpression  has  on  cellular 
proliferation.  In  MCA102,  lumican  overexpression  did  not  affect  proliferation.  In  Pan02 
however, lumican overexpression produced a significant increase in proliferation. This result is 35 
in direct contrast with previous reports of lumican’s effect on melanoma, osteosarcoma, murine 
embryonic fibroblasts, and HEK 293T [55, 62, 70, 118]. Although there is no consensus between 
lumican’s in vitro effects on MCA102 and Pan02, we have demonstrated that both cell lines 
behave consistently in vivo. We found lumican overexpression in MCA102 and Pan02 reduced 
the growth of subcutaneous tumors in syngenic mice. Moreover, since the effect of lumican on 
these cell lines in vitro is inconsistent, the reduction in tumor size is unlikely due to direct effects 
on the tumor cells. The reduction in tumor size is consistent with previous reports using induced 
oncogenic  fibroblasts  and  melanoma  cell  lines  [60,  62].  The  consistency  of  effects  in  vivo 
highlights the importance of the host microenvironment in cancer progression. 
Hematoxylin and eosin (H&E) staining and CD-31 localization of the extracted tumor 
sections revealed a reduced vessel density in lumican-overexpressing MCA102 and Pan02. This 
finding  suggests  that  lumican  may  perform  an  anti-angiogenic  role  in  the  tumor 
microenvironment. Myocardial vascularization increases in lum -/- fmod -/- knockout mice and 
Matrigel plug experiments have demonstrated that lumican can reduce vascularization induced 
by bFGF [66]. Recent reports of endothelial cells plated on lumican reveals reduced pseudotube 
formation [63] and previous research on tubulating endothelial cells has demonstrated expression 
of lumican increases during the resolution phase of angiogenesis in which vascularization ceases 
and the vessel returns to a state of angiostasis [66]. This angiostatic state can be observed in large 
resting vessels where expression of lumican is high [65]. Collectively, these results highlight the 
potential for lumican to function as a negative regulator of angiogenesis. 
Although  highly  resistant  to  apoptosis  when  quiescent,  endothelial  cells  are  very 
susceptible  to  a  particular  form  of  apoptosis  known  as  anoikis  during  angiogenesis  [119]. 
Anoikis is apoptosis resulting from the loss of cell adhesion to the ECM. Several known anti-36 
angiogenic proteins of the ECM including angiostatin, canstatin, thrombospondin-1, and decorin 
promote  apoptosis  in  the  invading  endothelial  cells  [110,  120-124].  In  the  living  organism, 
lumican overexpression alone was sufficient in reducing the vascular density and size of tumors. 
Upon analysis of colony-forming assays as well as caspase-3 cleavage, we report that lumican 
consistently  increases  susceptibility  to  Fas-induced  apoptosis  in  lumican-overexpressing 
endothelial cells;  an effect  observed in  endothelial  cells  cultured in  conditioned media from 
lumican-overexpressing tumor cells as well.  
Previous reports have demonstrated lumican preferentially binds to soluble Fas-L and 
increases  apoptosis.  Membrane  bound  Fas-L  is  also  expressed  in  a  variety  of  cancer  types, 
presumably as a means for immune evasion [72-77]. We identified the presence of Fas-L in 
equal  abundance  in  MCA102  and  Pan02  cells,  without  regard  to  lumican  overexpression 
suggesting that increased endothelial cell apoptosis is not due to increased tumor cell expression 
of  Fas-L.  Although  previous  reports  have  suggested  that  lumican  expression  may  drive  Fas 
receptor  expression,  our  analysis  of  MB114-Neo  and  MB114-Lum  cell  lysates  revealed  no 
significant difference in the level of Fas detected. However, the anti-apoptotic protein FLIP was 
found to be downregulated in the MB114-Lum cell line as compared to MB114-Neocell line. 
FLIP acts as a competitive inhibitor of caspases-8, effectively halting the caspase cascade and 
progression of apoptosis. By downregulating FLIP within the endothelial cells, lumican could 
increase the susceptibility to apoptosis, thereby preventing angiogenesis. 
 
Conclusion 
We have shown that lumican overexpression consistently reduces tumor growth in vivo 
regardless of its pleiotropic in vitro effects. Furthermore, this reduction in tumor growth is 37 
associated with reduced vascular density. Finally, we have provided evidence to support a Fas-
specific pro-apoptotic role for the SLRP lumican in the endothelium. 
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Figure 1. Confirmation of lumican overexpression 
Confirmation of lumican overexpression was performed on conditioned media from the 
MCA102 and Pan02 cell lines. TCA/DOC precipitation and detection with rabbit-anti-lumican 
(1:100)  revealed  little  or  no  endogenous  expression.  Ni-Ag  precipitation  and  detection  with 
mouse-anti-cMyc (1:1000) confirmed plasmid overexpression of lumican. 
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Figure 2. Lumican overexpression exhibits pleiotropic effects in vitro 
 
(A, B) Lumican-overexpressing cell lines and their corresponding control cell lines were cultured 
in Matrigel coated Boyden chambers and induced to invade. Lumican overexpression increased 
invasion in PanO2 cells but decreased invasion in MCA102 cells. Data is the average +/- 1SEM 
of at least four independent experiments. (C, D) Lumican-overexpressing and control cells were 
cultured in soft-agar. The areas of the resulting colonies were calculated from two dimensional 
measurements of colony diameter. Lumican increased MCA102 colony size but decreased 
PanO2 colony size. Data is presented as the average of three independent experiments +/- 1SEM. 
(E, F) Lumican-overexpressing PanO2 and MCA102 cells were cultured for 1 to 4 days. Each 
day, the relative number of cells was measured with WST-1 cell proliferation reagent. Lumican 
increased PanO2 proliferation, but did not affect MCA102 proliferation. Data is presented as the 
average of four independent experiments +/- 1SEM. (* indicates p<.05, Student’s T-Test) 
  
 
Figure 3.Lumican consistently reduces tumor growth in vivo 
Equal numbers of lumican-overexpressing MCA102 and Pan02 cells or their corresponding 
control counterparts were injected in triplicate into syngenic C57BL/6 mice. (A) Tumor volumes 
were calculated daily and are reported as the average for each day relative to the first day after 
inoculation that tumors appeared. Data is the average +/-1SEM of three independent 
experiments. (B) Tumor masses were recorded at time of removal. Data is the final tumor mass 
(mg) for each tumor. Midlines represent mean mass. (C) Photos depicting the actual tumors 
removed for each experiment.       (* indicates p<.05, Mann-Whitney rank sum test).
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Figure 4. Lumican overexpression reduces tumor vasculature 
(A) Lumican-overexpressing and control tumors were sectioned and stained for hematoxylin and 
eosin (H&E) and vessels were counted in each of 10 fields at 200x. Data is presented as the 
average number of vessels per field for each tumor type +/- 1SEM. (B) Lumican-overexpressing 
and control tumor sections were probed for the endothelial cell specific marker CD-31. Fewer 
vessels can be observed in the lumican-overexpressing tumors. 42 
 
Figure 5. Lumican enhances Fas-mediated apoptosis 
(A)  Confirmation  of  lumican  overexpression  was  performed  on  conditioned  media  from  the 
MB114  cell  line.  TCA/DOC  precipitation  and  detection  with  rabbit-anti-lumican  (1:100) 
revealed little or no endogenous expression. Ni-Ag precipitation and detection with mouse-anti-
cMyc  (1:1000)  confirmed  plasmid  overexpression  of  lumican.  (B)  Representative  MB114 
colonies formed after plating 500 cells. (C) Average amount of colony survival after plating 500 
cells. Data is presented as the average fold of colonies formed by MB114-Neo  +/- 1SD. (D) 
Control  or  Lumican-overexpressing  cells  were  cultured  in  the  presence  of  absence  of  Fas-
agonizing antibody Jo-2. Whole cell lysates were probed with anti-caspase-3 antibodies to detect 
apoptosis. (E) Conditioned media was collected from control and lumican-overexpressing tumor 
cells. The presence of lumican was confirmed by western blot. (F) MB114 endothelial cells were 
cultured  in  conditioned  media  from  control  or  lumican-overexpressing  tumor  cells  in  the 
presence or absence of Jo-2 antibodies. Apoptosis was monitored by western blot with anti-
caspase-3 antibodies. (G) Expression levels of FLIP, Fas, and Fas-L was detected in whole cell 
lysates from control or lumican-overexpressing MB114, MCA102, and Pan02 cells by western 
blot analysis. Actin served as a loading control. 
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CHAPTER 3 
 
ANALYSIS OF NOVEL ANGIOGENESIS TARGETS VIA TARGETED ANTI-
SENSE MORPHOLINO OLIGONUCLEOTIDE KNOCKDOWN IN TRANSGENIC 
ZEBRAFISH 
 
Introduction 
The extracellular matrix is a dynamic environment consisting of structural proteins as 
well as secretory signaling proteins. The expression and secretion of such proteins is of particular 
importance  in  regulating  angiogenesis.  Discovering  the  roles  played  by  novel  extracellular 
matrix proteins in vascularization is a crucial step in the process of creating new treatments for 
pathological angiogenesis.  
Our previous microarray analysis of sprouting endothelial cells has provided numerous 
novel targets, many of which have been confirmed by reverse transcription (RT) PCR. Over the 
last  decade,  anti-sense  morpholino  oligonucleotide  knockdown  of  specific  genes  in  early 
zebrafish embryos has proven to be an effective method in the pursuit of validating research 
targets. During this same period, transgenic zebrafish have been created which express GFP 
under  the  endothelial  fli1  promoter  and  dsRed  under  the  erythrocytic  gata1  promoter.  The 
combination of these two advances has established a novel method to assess the role specific 
genes play in the process of vascularization. 44 
Our  microarray  data  reveal  that  amongst  many  other  genes,  clu  (Clusterin),  grm 
(Gremlin-1), and serpine2 (Serpin E2) increased in expression during 25 hours of sprouting on 
matrix in the endothelial cell line MB114. During this same time period, npnt (Nephronectin) 
was among the genes found to decrease in expression. The aim of this study was to determine 
what role these genes play, if any, in the vascularization during the first five days of life using 
morpholino knockdown in the transgenic fli1
GFP/ gata1
dsRED zebrafish. Targets that demonstrate 
potential may then be expressed in cell culture and further studied as novel regulators of tumor 
angiogenesis. 
 
Materials and Methods 
Zebrafish  
Tg(fli1
GFP/ gata1
dsRED) Danio rerio (generously provided by Stephen Ekker, PhD, Mayo 
Clinic, Rochester, MN) were maintained  on a  14 hour light  10 hour  dark cycle at  28.5 ºC. 
Breeding  pairs  were  arranged  the  night  prior  to  embryo  injection  and  egg  fertilization  was 
triggered with the beginning of the light cycle. All experiments were performed in accordance 
with  the  animal  protocol  procedures  approved  by  the  Institutional  Animal  Care  and  Use 
Committee of Indiana State University.  
 
Confirmation of zebrafish mRNA expression 
Ten zebrafish embryos were collected at 2 hr, 6 hr, 2 d, 3 d, and 4 d in Tri-Reagent for 
the purpose of RNA extraction (T9424, Sigma-Aldrich, St. Louis, MO). Samples were prepared 
as per manufacturer’s instructions. Reverse transcription (RT) was performed using iScript 
cDNA synthesis kit (170-8891, Bio-Rad, Hercules, CA) as per manufacturer’s instructions. 45 
Oligo primers were synthesized for the zebrafish Clusterin (fwd 5’-
AATCCGTCGCAATTCTTTCGGCTG-3’) (rev 5’-TTCCTGTGCCACCACTTCAGAGAA-3’), 
Gremlin-1 (fwd 5’-ATACAGTCCAAACCAGTCGGAGCA -3’) (rev 5’-
TCCGTAGCAGAAGCGGTTGATGAT -3’), Nephronectin (fwd 5’-
GTAAGCACCGCTGCATGAACACAT-3’) (rev 5’-TGACGTACTGAAGGTCAAAGCCGT-
3’), SerpinE2 (fwd 5’-TCAGATCTGGGTCTGCAGGTGTTT-3’) (rev 5’-
ACCACACTGGGAATCTGGCCTTTA-3’), and GAPDH (fwd 5’-
AGGCTTCTCACAAACGAGGACACA-3’) (rev 5’-ATCAATGACCAGTTTGCCGCCTTC-3’) 
(Integrated DNA Technologies, Skokie, IL). PCR was performed for 40 cycles (95º53º72º) 
and amplified products were analyzed via gel electrophoresis on 2% agarose. 
 
Morpholino design 
Morpholinos were designed to prevent transcription by binding approximately 50-75 bp 
upstream of the target start codon. Anti-sense morpholino oligonucleotides were synthesized for 
the zebrafish Clusterin (5’-ACAGAGGTCAGAGACATAGTAGATC-3’), Gremlin-1 (5’-
TAAATCATAGGCTATAAATATATAT -3’), Nephronectin (5’-
GGTCTGTGAATGGGAATGATGATGA -3’), and SerpinE2 (5’-
AGATGGAGAGCTCGTGTCTTCCGCG -3’) (Gene Tools, LLC, Philomath, OR). Antisense 
zebrafish p53 morpholino was designed by the manufacturer previously (5’-
GCGCCATTGCTTTGCAAGAATTG -3’) (Gene Tools, LLC, Philomath, OR). 
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Morpholino injection and analysis 
  The  PV830  pneumatic  PicoPump  (World  Precision  Instruments,  Sarasota,  FL)  was 
utilized in the delivery of morpholino to the target embryos. Morpholinos were suspended in 
deionized water and further diluted with phenol red such that one 0.3 nl injection delivered 4 ng 
of  morpholino  to  an  embryo.  Multiple  injections  were  utilized  to  deliver  up  to  12  ng  of 
morpholino. Further dilutions were required to establish a 1 ng per 0.3 nl injection solution. 
When  co-injected,  anti-p53  morpholino  was  utilized  at  1.5  times  the  amount  of  the  target 
morpholino  as  described  previously  [81].  Control  fish  were  injected  with  phenol  red  alone. 
Approximately 10 embryos were injected with a given dose or empty vehicle. Embryos were 
dechorionated at 24 hr and observed under bright field and fluorescent light and photographed. 
Proper dosage was determined experimentally. 
 
Results 
Confirmation of target expression via RT-PCR of early embryos 
To establish the temporal expression patterns of the target genes, and ensure they are 
indeed expressed during our period of observation, we performed reverse transcription (RT) PCR 
at time points ranging from 2 hours to 4 days. Analysis of the zebrafish mRNA via RT-PCR 
revealed that clusterin is expressed as early as day 2, and gremlin-1, nephronectin, and serpinE2 
are  expressed  as  early  as  2  hours  post  fertilization.  The  housekeeping  gene  GAPDH  was 
expressed at all time points as a control (Fig. 1) 
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Effects of morpholinos on zebrafish development 
  Increasing doses of anti-clusterin morpholino (up to 12 ng) had no apparent effect on 
zebrafish development as morpholino-treated fish were indistinguishable from vehicle-injected 
controls.  Conversely,  fish  treated  with  4  ng  anti-gremlin-1  morpholino  possessed  a  less 
developed vasculature compared to controls at 1 day. Additionally, injection with as little as 1 ng 
anti-nephronectin morpholino resulted in delayed vascularization as compared to control fish. 
Finally, treatment with 4 ng anti-serpinE2 was lethal in the majority of fish tested. The one 
surviving fish possessed greatly underdeveloped vasculature at day 1 as compared to controls 
(Fig. 2).  
 
Discussion 
  Because  they  share  many  organs  and  possess  similar  genomes,  zebrafish  remain  an 
excellent model for human conditions [79]. Zebrafish are a particularly useful model for the 
rapid screening of potential angiogenic targets. Advances in transgenic zebrafish lines, including 
those expressing GFP-vasculature and dsRed-erythrocytes, as well as morpholino technology 
have enabled researchers to pursue investigations more simply and effectively than can be done 
in other model systems [80, 82-83]. Morpholino screening has led to the establishment of entire 
databases describing the effects  of this  knockdown technology  [120]. Researchers also  have 
suggested approaches that combine the Tg(fli1
GFP/ gata1
dsRED) zebrafish with an in vivo tumor 
model system to study tumor angiogenesis [121]. 
We report the effects of anti-sense morpholino oligonucleotides against multiple targets 
suspected to play a role in angiogenesis during the first five days of embryonic development in 
zebrafish.  Clusterin  has  been  implicated  in  angiogenesis  and  in  a  variety  of  cancers  and  is 48 
thought  to  play  a  role  in  regulating  apoptosis  [85-95].  However,  injection  of  the  anti-sense 
morpholino oligonucleotide against clusterin failed to evoke any response within the zebrafish 
vasculature over the course of the first five days of development, even at doses as high as 12 ng. 
This suggests that in spite of previous data, clusterin is not important in regulating angiogenesis 
during  early  zebrafish  development.  Conversely,  morpholinos  against  the  targets  gremlin-1, 
nephronectin,  and  serpinE2  all  inhibited  or  delayed  vascular  neogenesis  to  some  degree, 
suggesting that these are important for early zebrafish angiogenesis regulation. Gremlin-1 has 
been implicated in angiogenesis and is strongly expressed in the endothelial cells of lung tumor 
vasculature [98-100]. Similarly, nephronectin has been implicated in several cancers and is a 
known  regulator  of  zebrafish  heart  development  [102-104].  SerpinE2  has  not  been  directly 
implicated in angiogenesis, but its ability to alter the production of matrix proteins is thought to 
mediate cancer cell invasion [105-107]. 
Future experiments will be required to determine the minimally effective doses for these 
morpholinos. Additionally, co-injection with anti-p53 morpholino is required to confirm that the 
observed effects are vascular-specific. Targets will then be overexpressed in cell culture models 
to be further characterized. 
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Figure 1. Confirmation of mRNA expression in early embryo and vessel anatomy 
(A) Results of RT-PCR demonstrate the presence or absence of particular mRNAs at the given 
time points. The housekeeping gene GAPDH served as a positive control for mRNA. (B) GFP 
image of control fish at 24 hr time point. Intersegmental vessels (ISV) and dorsal aorta (DA) are 
indicated. 
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Figure 2. Observed effects of morpholino knockdowns 
Bright field images demonstrate overall morphology of embryos at 24 hr. GFP images highlight 
the developing vasculature. Age matched control embryos are represented in the bottom two 
rows. Intersegmental vessels (ISV) are shown in lower left hand corner of images. 
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